CPT 80374 Stereoisomer Analysis Reimbursement

CPT code 80374 identifies laboratory analysis that measures or detects stereoisomers within a single drug class in patient specimens. This test matters nationally because stereoisomer-specific results can affect clinical interpretation of drug exposure, toxicity, therapeutic monitoring, and forensic or compliance testing. Distinguishing enantiomers and other stereoisomers helps clinicians and laboratories refine diagnostic conclusions and drug-monitoring strategies.

Key payers considered in this profile include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context, typical sites of service, and how payers approach coverage and claims handling at a high level. The report summarizes common modifiers associated with laboratory services and highlights benchmarking and policy considerations relevant to laboratories and billing teams.

This summary provides a national perspective on clinical use cases and billing implications without state-specific policy detail. It outlines the operational setting for the service and what professionals should expect when coding and reporting stereoisomer-specific drug analyses under CPT code 80374.

Billing Code Overview

CPT code 80374 describes laboratory testing that measures the amount of or detects the presence of stereoisomers of a single drug class in a patient specimen. Stereoisomers are compounds with the same chemical components in the same order but different spatial configurations; enantiomers are mirror-image stereoisomers that can differ in biological activity. This service identifies and quantifies those stereoisomer forms when distinguishing biological effects or metabolism of a drug class is clinically relevant.

Service type: Laboratory test — stereoisomer-specific drug analysis

Typical site of service: Clinical laboratory or hospital laboratory

Data not available in the input.

Clinical Context

A 38-year-old patient presents for evaluation after being prescribed a chiral medication (for example, certain beta-blockers or amphetamine-based stimulants) and exhibits atypical response or suspected nonadherence. The clinician orders specialized toxicology to measure stereoisomer concentrations in serum or urine to distinguish active enantiomer levels, confirm therapeutic compliance, or investigate adverse effects. The clinical workflow begins with the ordering clinician (e.g., psychiatry, pain management, or primary care) selecting the stereoisomer assay (CPT 80374) on the laboratory requisition. The patient provides a specimen at an outpatient phlebotomy or clinic site. The specimen is transported to a clinical laboratory where a lab analyst performs chiral separation and quantitation using techniques such as chiral chromatography coupled with mass spectrometry. Results are reported to the ordering provider and integrated into the electronic health record for medication management, dose adjustment, or further toxicology interpretation. Typical sites of service include hospital outpatient laboratories, independent clinical reference laboratories, and outpatient clinics with specimen collection capability.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when reporting only the professional (interpretive) component of the laboratory service if applicable in the billing framework.

Taxonomy Code	Specialty	Notes
362X00000X	Clinical Pathology	Laboratory directors and clinical pathologists overseeing toxicology testing.
207R00000X	Psychiatry & Neurology	Psychiatrists ordering stereoisomer quantitation for psychotropic agents.
207L00000X	Pain Medicine	Pain specialists managing chiral opioid or analgesic therapy and monitoring.
207Q00000X	Internal Medicine	Primary care and internists ordering confirmatory therapeutic drug monitoring.
2080P0208X	Emergency Medicine	Emergency physicians when stereoisomer testing informs acute toxicology decisions.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F11.20`	Opioid dependence, uncomplicated	Relevant when distinguishing active opioid enantiomers for monitoring therapy or suspected diversion.
`F15.20`	Other stimulant dependence, uncomplicated	Relevant for amphetamine-type stimulants that have enantiomeric forms affecting clinical effect.
`T40.2X5A`	Poisoning by other opioids, intentional self-harm, initial encounter	Used in acute toxicology where enantiomer quantitation informs treatment.
`R78.89`	Other abnormal findings of blood chemistry	May be used when abnormal toxicology results require stereoisomer-specific testing.
`Z79.899`	Other long term (current) drug therapy	Used when chronic chiral drug therapy necessitates monitoring of active stereoisomer levels.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80307`	Drug confirmation, qualitative or quantitative, by definitive drug testing (e.g., chromatographic, mass spectrometric), per drug class	Initial confirmation testing often precedes or accompanies stereoisomer-specific analysis; used when definitive identification of parent drug is required.
`80305`	Drug confirmation, qualitative or quantitative, by definitive drug testing, per drug class (immunoassay screening is separate)	Used for confirmatory definitive testing workflows that may be performed before ordering stereoisomer quantitation.
`80375`	Measurement of specific enantiomer or stereoisomer panels (if applicable)	Frequently reported in series when additional or panel stereoisomer analyses are performed alongside `80374`.
`83001`	Drug assay, therapeutic drug monitoring (immunoassay)	Routine therapeutic drug monitoring may be used in parallel; if immunoassay screening is performed prior to chiral separation, this code is part of the workflow.
`90281`	Specimen processing for specialized testing (example code for logistics)	Codes for specimen handling or shipping to reference labs are commonly used in the chain-of-custody and processing steps when stereoisomer testing is sent out.

OpenPayer

Summary & Overview

CPT 80374: Stereoisomer-Specific Drug Analysis